Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combination of cdk4/6 inhibitor combined with her2 inhibitor for gastric cancer treatment

An inhibitor, gastric cancer technology, applied in the field of CDK4/6 inhibitors combined with HER2 inhibitors, can solve the problems of complex and unclear drug resistance mechanisms

Active Publication Date: 2020-06-16
BEIJING CANCER HOSPITAL PEKING UNIV CANCER HOSPITAL +1
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] As we all know, drug resistance is the main reason for the failure of drug treatment. The high heterogeneity of gastric cancer cells and the complex tumor microenvironment make the drug resistance mechanism very complicated. clear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination of cdk4/6 inhibitor combined with her2 inhibitor for gastric cancer treatment
  • Combination of cdk4/6 inhibitor combined with her2 inhibitor for gastric cancer treatment
  • Combination of cdk4/6 inhibitor combined with her2 inhibitor for gastric cancer treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1, Proposal of CDK4 / 6 Inhibitor Combined with HER2 Inhibitor Therapeutic Combination

[0033] Reliable exploration of treatment strategies after drug resistance must rely on translational research to succeed, and "clinical trials guided by preclinical research" is the only way. Based on this, the inventors of the present invention designed and carried out chain research.

[0034] The most important prerequisite for the study of drug resistance mechanism is to have the best preclinical drug resistance model. The drug resistance model based on traditional cell line screening is greatly different from the patient's tumor characteristics, so it is no longer the best choice for drug resistance research.

[0035] In the early stage, the inventors of the present invention used real-time endoscopic biopsy of trace amounts of advanced gastric cancer tissue to construct a large-scale mouse subcutaneous xenograft (patient-derived tumor xenograft, PDX) model based on patient...

Embodiment 2

[0048] Example 2. The curative effect of CDK4 / 6 inhibitor combined with HER2 inhibitor in patients with gastric cancer

[0049] 1. The course and treatment of patient 1

[0050] Patient 1: Sun **, female

[0051] In February 2017, it was confirmed to be poorly differentiated gastric adenocarcinoma; the postoperative pathological stage was pT4N1M0 (stage III), and immunohistochemistry showed HER2 positive (3+); postoperative oxaliplatin combined with fluorouracil in March 2017 chemotherapy.

[0052] In August 2017, reexamination found liver metastases. Considering the disease progression, he successively received paclitaxel combined with platinum (disease progression), irinotecan combined with fluorouracil and apatinib (disease progression), and docetaxel combined with fluorouracil (disease progression). ), paclitaxel liposome (disease progression) multi-line therapy, the disease progression was reviewed in July 2018, and it was found that the patient's disease still progress...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses CDK4 / 6 inhibitor and HER2 inhibitor combination for gastric cancer treatment and application of a CDK4 / 6 inhibitor and a HER2 inhibitor to preparation of a composition for treatment of HER2 positive gastric cancer patients with drug tolerance. In gastric cancer clinical research history, the patients with drug tolerance after first-line treatment are slightly benefited no matter which drug / scheme is adopted. Excellent benefits achieved by use of the treatment combination are rare, and the treatment combination is put forward for the first time on the basis of preclinical study and verified through clinical researches on patients and is a landmark major breakthrough in the field of gastric cancers.

Description

technical field [0001] The present invention relates to the combination of CDK4 / 6 inhibitor combined with HER2 inhibitor for the treatment of gastric cancer. Background technique [0002] Asia is the region with the highest incidence of gastric cancer in the world, and China accounts for 47% of the world's new cases each year. The latest Chinese tumor registration statistics show that the incidence and mortality of gastric cancer rank among the top three among malignant tumors in the country, seriously endangering the health of Chinese people. About 80% of Chinese gastric cancer patients are diagnosed with late disease stage (distant metastasis or locally advanced stage), who lose the chance of radical surgery or have a high recurrence and metastasis rate after surgery, and drug therapy is the main treatment for patients with late stage. In the past few decades, chemotherapy has been the cornerstone of gastric cancer drug treatment, but the limited benefits and high toxicit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/06A61K31/4709A61P35/00A61P35/04
CPCA61K31/4709A61K45/06A61P35/00A61P35/04A61K2300/00
Inventor 沈琳高静龚继芳李健张小田
Owner BEIJING CANCER HOSPITAL PEKING UNIV CANCER HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com